Yuan Jing Ping, Wang Lin Wei, Qu Ai Ping, Chen Jia Mei, Xiang Qing Ming, Chen Chuang, Sun Sheng-Rong, Pang Dai-Wen, Liu Juan, Li Yan
Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan, Hubei, China.
School of Computer, Wuhan University, Wuhan, Hubei, China.
PLoS One. 2015 Apr 9;10(4):e0122734. doi: 10.1371/journal.pone.0122734. eCollection 2015.
As a marker for tumor cell proliferation, Ki67 has important impacts on breast cancer (BC) prognosis. Although immunohistochemical staining is the current standard method, variations in analytical practice make it difficult for pathologists to manually measure Ki67 index. This study was to develop a fluorescent spectrum-based quantitative analysis of Ki67 expression by quantum-dots (QDs) multiple imaging technique.
A QDs-based in situ multiple fluorescent imaging method was developed, which stained nuclear Ki67 as red signal and cytoplasmic cytokeratin (CK) as green signal. Both Ki67 and CK signals were automatically separated and quantified by professional spectrum analysis software. This technique was applied to tissue microarrays from 240 BC patients. Both Ki67 and CK values, and Ki67/CK ratio were obtained for each patient, and their prognostic value on 5-year disease free survival was assessed.
This method simultaneously stains nuclear Ki67 and cytoplasmic CK with clear signal contrast, making it easy for signal separation and quantification. The total fluorescent signal intensities of both Ki67 sum and CK sum were obtained, and Ki67/CK ratio calculated. Ki67 sum and Ki67/CK ratio were each attributed into two grades by X-tile software based on the best P value principle. Multivariate analysis showed Ki67 grade (P = 0.047) and Ki67/CK grade (P = 0.004) were independent prognostic factors. Furthermore, area under curve (AUC) of ROC analysis for Ki67/CK grade (AUC: 0.683, 95%CI: 0.613-0.752) was higher than Ki67 grade (AUC: 0.665, 95%CI: 0.596-0.734) and HER-2 gene (AUC: 0.586, 95%CI: 0.510-0.661), but lower than N stage (AUC: 0.760, 95%CI: 0.696-0.823) and histological grade (AUC: 0.756, 95%CI: 0.692-0.820) on predicting the risk for recurrence.
A QDs-based quantitative and in situ multiple imaging on Ki67 and CK was developed to improve Ki67 assessment in BC, and Ki67/CK grade had better performance than Ki67 grade in predicting prognosis.
作为肿瘤细胞增殖的标志物,Ki67对乳腺癌(BC)的预后具有重要影响。尽管免疫组织化学染色是目前的标准方法,但分析实践中的差异使得病理学家难以手动测量Ki67指数。本研究旨在通过量子点(QD)多重成像技术开发一种基于荧光光谱的Ki67表达定量分析方法。
开发了一种基于量子点的原位多重荧光成像方法,将细胞核中的Ki67染成红色信号,细胞质中的细胞角蛋白(CK)染成绿色信号。Ki67和CK信号均通过专业光谱分析软件自动分离和定量。该技术应用于240例BC患者的组织芯片。获得每位患者的Ki67和CK值以及Ki67/CK比值,并评估它们对5年无病生存率的预后价值。
该方法同时对细胞核中的Ki67和细胞质中的CK进行染色,信号对比清晰,便于信号分离和定量。获得了Ki67总和与CK总和的总荧光信号强度,并计算了Ki67/CK比值。基于最佳P值原则,通过X-tile软件将Ki67总和与Ki67/CK比值分别分为两个等级。多因素分析显示,Ki67等级(P = 0.047)和Ki67/CK等级(P = 0.004)是独立的预后因素。此外,Ki67/CK等级的ROC分析曲线下面积(AUC:0.683,95%CI:0.613 - 0.752)高于Ki67等级(AUC:0.665,95%CI:0.596 - 0.734)和HER-2基因(AUC:0.586,95%CI:0.510 - 0.661),但低于N分期(AUC:0.760,95%CI:0.696 - 0.823)和组织学分级(AUC:0.756,95%CI:0.692 - 0.820)对复发风险的预测。
开发了一种基于量子点的Ki67和CK定量原位多重成像方法,以改善BC中Ki67的评估,并且Ki67/CK等级在预测预后方面比Ki67等级表现更好。